Defendant: Pfizer Inc. | Category: Pharmaceutical & Medical Devices | Added: 2026-07-20
Alleged Issue
A class action alleged that Chantix (varenicline) tablets contained N-nitroso-varenicline (NNV), a probable human carcinogen, above acceptable daily intake limits.
Eligibility
U.S. residents who purchased Chantix between September 29, 2015 and September 17, 2021.
Estimated Payout
Pro rata share of $44M settlement fund
Claim Deadline
2026-09-14
Background
The litigation In re: Chantix (Varenicline) Products Liability Litigation was consolidated as MDL No. 3092 in the Northern District of Alabama. The settlement received preliminary approval in 2025, covering all U.S. residents who purchased Chantix during the class period. The $44 million settlement fund covers consumer reimbursement claims for purchase costs of contaminated Chantix tablets. Claims must be submitted by September 14, 2026. Administered by Kroll Settlement Administration.